Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 81-86

  Vincent, J ^a   Teng, R ^a   Dogolo, L C ^a   Willavize, S A ^a   Friedman, H L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; TROVAFLOXACIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET SPECTROSCOPY;

EID: 0030836478     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.81     Document Type: Article

References (24)

1. Bertino, J. S. & Walker, J. W. (1987). Reassessment of theophylline toxicity: serum concentrations, clinical course, and treatment. Archives of Internal Medicine 147, 757-60.
2. Shannon, M. & Lovejoy, F. H. (1990). The influence of age vs peak serum concentration on life-threatening events after chronic theophylline intoxication. Archives of Internal Medicine 150, 2045-8.
3. Rall, T. W. (1990). Drugs used in the treatment of asthma: the methylxanthines, cromolyn sodium, and other agents. In Goodman and Oilman's The Pharmacological Basis of Therapeutics, 8th edn (Gilman, A. G., Rall, T. W., Nies, A. S. & Taylor, P., Eds), pp. 618-37. Pergamon, New York, NY.
4. McEvoy, G. K., Litvak, K. & Welsch, O. H. (1995). AHFS Drug Information 1995, pp. 2506-13. American Society of Health-System Pharmacists, Bethesda, MD.
5. Robson, R. A. (1992). The effects of quinolones on xanthine pharmacokinetics. American Journal of Medicine 92, Suppl. 4A, 22S-5S.
6. Parent, M. & LeBel, M. (1991). Meta-analysis of quinolone-theophylline interactions. DICP 25, 191-4.
7. Brouwers, J. R. B. J. (1992). Drug interactions with quinolone antibacterials. Drug Safety 7, 268-81.
8. Niki, Y., Hashiguchi, K., Okimoto, N. & Soejima, R. (1992). Quinolone antimicrobial agents and theophylline. Chest 101, 881.
9. Sörgel, F. & Kinzig, M. (1993). Pharmacokinetics of gyrase inhibitors, Part 2: renal and hepatic elimination pathways and drug interactions. American Journal of Medicine 92, Suppl. 3A, 56S-69S.
10. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
11. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
12. Girard, A. E., Faiella, J. A., Cimochowski, C. R. & Brighty, K. E. (1993). In vitro oral activity of CP-99,219 in models of acute and localized infection. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1510, p. 395. American Society for Microbiology, Washington, DC.
13. Girard, D., Brighty, K. E. & Gootz, T. D. (1993). CP-99,2129, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone: pharmacokinetics in animals. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1511, p. 395. American Society for Microbiology, Washington, DC.
14. Teng, R., Khosla, N. B., Renouf, D. N, Girard, G., Silber, B. M., Foulds, G. et al. (1993). Pharmacokinetics of CP-99,219, a new oral quinolone antibiotic, in Sprague-Dawley rats, beagle dogs and cynomolgus monkeys. Pharmaceutical Research 10, S336.
15. Neu, M. C. & Chin N.-X. (1994). In-vitro activity of the new fiuoroquinolone, CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
16. 14C]CP-99,219 into gastric tissue of Long-Evans rats and Swiss-Webster mice following intravenous administration. In Abstracts of the Seventh European Conference of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995. Abstract 747, p. 144. European Society of Clinical Microbiology and Infectious Diseases.
17. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
18. Teng, R., Liston, T. E. & Harris, S. (1996). Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 37, 955-63.
19. Kinberger, B. & Holmén, A. (1982). Simultaneous determination of acetaminophen, theophylline and salicylate in serum by high-performance liquid chromatography. Journal of Chromatography 229, 492-7.
20. Wenk, M., Eggs, B. & Follath, F. (1983). Simultaneous determination of diprophylline, proxyphylline and theophylline in serum by reversed-phase high-performance liquid chromatography. Journal of Chromatography 276, 341-8.
21. Teng, R., Tensfeldt, T. G., Liston, T. E. & Foulds, G. (1995). Determination of trovafloxacin, a new oral quinolone antibiotic, in biological samples by reversed-phase high performance liquid chromatography. Journal of Chromatography 675, 53-9.
22. Wijnands, W. J. A., van Herwaarden, C. L. A. & Vree, T. B. (1984). Enoxacin raised plasma theophylline concentrations. Lancet ii, 108-9.
23. Wijnands, W. J. A., Vree, T. B. & van Herwaarden, C. L. A. (1985), Enoxacin decreases the clearance of theophylline in man. British Journal of Clinical Pharmacology 20, 583-8.
24. Beckmann, J., Elsässer, W., Gundert-Remy, U. & Hertrampf, R. (1987). Enoxacin - a potent inhibitor of theophylline metabolism. European Journal of Clinical Pharmacology 33, 227-30.